This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
L02BX Other hormone antagonists and related agents
RX_L02BX
No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
2302 |
4. Check minimum number of events
Min. number of events
3
|
2302 |
5. Include endpointsNone |
2302 |
6. Filter based on genotype QC (FinnGen only) |
2092 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- First used in FinnGen datafreeze
- DF3
Similar endpoints
↥List of similar endpoints to
L02BX Other hormone antagonists and related agents
based on the number of shared cases.
Similar with more cases:
- Malignant neoplasm of prostate, including Hilmo
- malignant neoplasm of male genital organs, including Hilmo
- Solid cancers, including Hilmo
- Malignant neoplasm, wide definition
- Malignant neoplasm, including Hilmo
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 2092 | - | 2092 |
| Unadjusted period prevalence (%) | 0.96 | - | 0.96 |
| Median age at first event (years) | 73.91 | - | 73.91 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 2168
- Matched controls
- 21680
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
L02AE04
ATC
triptorelin; parenteral
14.3
309.4
296
237
XX3DW
NOMESCO Finland
Time consuming IT work
6.9
307.7
823
1757
H02AB02
ATC
dexamethasone; systemic
11.0
307.7
956
1451
WF049
NOMESCO Finland
Radiotherapy of metastasis
17.7
307.7
663
527
Y77
ICPC
Malignant neoplasm prostate
44.0
307.7
1359
798
KE3AT
NOMESCO Finland
Transrectal gold marker implantation in prostate under ultrasound guidance
10.2
307.7
456
550
L02BB03
ATC
bicalutamide; oral
18.6
307.7
789
648
Z51.5
ICD-10 Finland
Palliative care
6.7
307.7
824
1828
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
14.3
307.7
1678
4193
L02AE02
ATC
leuprorelin; implant, parenteral
19.8
307.7
1174
1220
352
Kela drug reimbursment
Abiraterone and enzalutamide
242.3
307.7
798
52
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
18.9
307.7
696
530
WD225
NOMESCO Finland
Demanding therapy of methastized malignancy with hormones
63.1
307.7
394
76
1523, ,
Kela drug reimbursment
78.4
307.7
444
71
163
Kela drug reimbursment
Abiraterone and enzalutamide
280.7
307.7
1070
75
M05BX04
ATC
denosumab; parenteral
35.4
307.7
942
460
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
13.4
307.7
533
515
NK6AN
NOMESCO Finland
Total body bone isotope imaging
18.7
307.7
572
407
C79.5
ICD-10 Finland
Secondary malignant neoplasm of bone and bone marrow
45.8
307.7
761
253
116
Kela drug reimbursment
Prostate cancer
489.1
307.7
2118
1728
L02BB04
ATC
enzalutamide; oral
138.3
307.7
872
105
L02BX03
ATC
abiraterone; oral
647.5
307.7
988
28
ZX112
NOMESCO Finland
Subcutaneous
16.6
307.7
306
212
L02BX02
ATC
degarelix; parenteral
1083.8
307.7
1458
41
3054, ,
Kela drug reimbursment
78.2
307.7
443
71
C61
ICD-10 Finland
Malignant neoplasm of prostate
1468.8
307.7
2160
3254
WF002
NOMESCO Finland
Radical radiotherapy
8.3
307.7
764
1338
WD205
NOMESCO Finland
Therapy of methastized malignancy with hormones
81.2
307.7
371
55
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
157.1
307.7
2088
3088
A03FA01
ATC
metoclopramide; systemic, rectal
6.1
307.7
997
2670
L03AA13
ATC
pegfilgrastim; parenteral
17.6
307.7
432
303
KE1AT
NOMESCO Finland
Biopsy of prostata with ultrasoudnguidance
11.6
307.7
1137
1885
YL1BD
NOMESCO Finland
Extensive CT examination of pelvis for dose design of radiotherapy
11.8
307.7
384
387
JN4AD
NOMESCO Finland
Body CT examination
5.4
301.6
841
2282
L02BX04
ATC
relugolix; oral
109.7
298.3
153
15
R74.8
ICD-10 Finland
Abnormal levels of other serum enzymes
5.7
289.6
693
1641
WD305
NOMESCO Finland
Simple therapy of methastized malignancy with biomodifiers
20.1
282.9
223
123
WZC00
NOMESCO Finland
Treatment plan or consultation
4.8
278.7
1388
5854
JN4BD
NOMESCO Finland
Extensive body CT
5.4
277.8
721
1826
N02AA05
ATC
oxycodone; systemic
4.7
275.6
1049
3608
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
7.8
274.4
431
671
L03AA14
ATC
lipegfilgrastim; parenteral
27.7
256.0
176
69
YL1AD
NOMESCO Finland
CT examination of pelvis for dose design of radiotherapy
9.5
240.8
307
371
WF004
NOMESCO Finland
Palliative radiotherapy
10.3
240.7
286
315
WVA30, ,
SPAT
6.2
234.8
465
912
XX1XQ
NOMESCO Finland
Other SPECT-CT
123.6
230.7
117
10
XKD00
NOMESCO Finland
Uroflowmetry
4.0
221.5
1241
5429
C77.8
ICD-10 Finland
Secondary and unspecified malignant neoplasm: Lymph nodes of multiple regions
33.1
207.7
134
43
WD215
NOMESCO Finland
Multiple therapy of methastized malignancy with hormones
64.3
199.2
110
18
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
3.7
191.1
1058
4482
L02AE03
ATC
goserelin; implant
15.4
186.0
166
116
XX9AN
NOMESCO Finland
Complementary isotope examination or additional picture
53.0
185.2
106
21
A04AA02
ATC
granisetron; systemic, transdermal
5.7
182.7
385
791
1CD02, ,
NOMESCO Finland
57.0
173.6
98
18
A79
ICPC
Malignancy NOS
11.4
170.7
184
175
R86.0
ICD-10 Finland
Abnormal findings in specimens from male genital organs, abnormal level of enzymes
6.2
167.1
312
570
A04AA01
ATC
ondansetron; systemic, rectal
5.1
164.6
396
910
YJ2VG
NOMESCO Finland
MRI examination of pelvis with high intensity magnet for dose design of radiotherapy
8.2
164.4
232
314
C77.5
ICD-10 Finland
Secondary and unspecified malignant neoplasm: Intrapelvic lymph nodes
30.8
156.5
103
35
NK6BQ
NOMESCO Finland
Whole body extensive bone SPET with low dose CT
14.7
153.8
140
101
ZX090
NOMESCO Finland
Other technic of radiotherapy
8.2
151.8
213
286
D40.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Prostate
7.2
151.7
241
372
2BX02, ,
NOMESCO Finland
64.7
146.8
81
13
G03HA01
ATC
cyproterone; systemic
14.1
138.3
129
97
KE1DR
NOMESCO Finland
Prostate metabolic PET with CT
18.9
138.1
110
61
ZX070
NOMESCO Finland
Intensity modified radiotherapy
7.9
137.7
197
270
YN7AD
NOMESCO Finland
CT examination of spine for dose design of radiotherapy
27.4
134.5
92
35
M87.1
ICD-10 Finland
Osteonecrosis due to drugs
27.6
131.8
90
34
NK6AQ
NOMESCO Finland
Whole body bone SPET with low dose CT
24.6
129.2
92
39
SPAT1256
SPAT
Intramuscular and subcutaneous injection
2.9
125.5
1310
7466
XX7FT
NOMESCO Finland
Radioyttrium therapy with connected antibody
226.6
125.2
128
6
JN5ER
NOMESCO Finland
PET-CT of receptors in whole body
14.9
124.4
112
79
N13.3
ICD-10 Finland
Other and unspecified hydronephrosis
6.8
117.0
191
302
YN7BD
NOMESCO Finland
Extensive CT examination of spine for dose design of radiotherapy
32.3
115.8
75
24
WZC30
NOMESCO Finland
Teaching
3.1
115.8
675
2794
A06AH03
ATC
naloxegol; oral
9.2
115.7
144
166
TKE00
NOMESCO Finland
Needle biopsy of prostate
3.8
104.3
370
1121
JN4LR
NOMESCO Finland
Extensive PET-CT of receptors in whole body
36.6
102.4
64
18
U77
ICPC
Malignant neopl urinary tract other
25.8
100.3
70
28
Y06
ICPC
Prostate symptom/complaint
3.9
97.7
324
935
PJD64
NOMESCO Finland
Laparoscopic dissection of iliac lymph nodes
7.4
96.0
143
204
C77.2
ICD-10 Finland
Secondary and unspecified malignant neoplasm: Intra-abdominal lymph nodes
15.1
93.3
83
57
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
4.3
91.5
259
665
WF090
NOMESCO Finland
Profylactic radiotherapy
10.0
90.4
105
110
YX9AD
NOMESCO Finland
Other CT eamination for dose design of radiotherapy
5.5
86.0
173
334
L02BB05
ATC
apalutamide; oral
25.2
83.9
59
24
3031
Kela drug reimbursment
Apalutamidi
24.2
82.6
59
25
1528, ,
Kela drug reimbursment
23.8
80.7
58
25
ZX080
NOMESCO Finland
Image guided radiotherapy
7.1
78.1
121
180
ZX112, ,
SPAT
14.7
77.8
70
49
KE1BE
NOMESCO Finland
Rectal ultrasound examinaiton of prostata
2.5
76.0
637
3081
KEC01
NOMESCO Finland
Percutaneous endoscopic radical prostatectomy
4.3
75.6
211
534
K62.7
ICD-10 Finland
Radiation proctitis
8.3
70.2
94
118
XJH00
NOMESCO Finland
Transanal ultrasonography
2.8
70.2
430
1775
XX7AT
NOMESCO Finland
Radiation therapy with Radium-223
347.8
67.9
68
*
KBV15
NOMESCO Finland
Cystoscopic change of ureteral stent
11.6
67.5
70
62
WB223
NOMESCO Finland
Demanding adjuvant hormone therapy of malignancy
10.8
66.8
73
70
R33
ICD-10 Finland
Retention of urine
2.6
66.3
495
2249
ZXC96
NOMESCO Finland
Robot assisted procedure
4.2
62.4
177
452
KH1BT
NOMESCO Finland
Urinary tract cathetrisation with X-ray guidance
6.4
61.6
104
169
J01MA02
ATC
ciprofloxacin; systemic
2.1
61.3
1148
7566
KH1FT
NOMESCO Finland
Exchange of urinary catheter with radiological guidance
10.1
59.8
68
69
A49.9
ICD-10 Finland
Bacterial infection, unspecified
2.4
58.6
487
2311
XX7LT
NOMESCO Finland
Lutetium-177-PSMA treatment
151.5
56.1
59
*
WB203
NOMESCO Finland
Simple adjuvant hormone therapy of malignancy
19.4
53.7
42
22
WF003
NOMESCO Finland
Adjuvant radiotherapy
4.4
53.2
140
337
WW500
NOMESCO Finland
Blood transfusion
3.6
52.7
185
548
ZX120
NOMESCO Finland
Intravenous
2.7
52.6
323
1322
ZX013
NOMESCO Finland
Radiotherapy with large shaped fields - SSD therapy
9.5
51.1
61
66
KEB00
NOMESCO Finland
Biopsy of prostate
4.8
50.3
118
259
SPAT1254
SPAT
Administration of medicine
2.3
50.2
459
2257
G04CA02
ATC
tamsulosin; oral
2.0
49.9
1290
9266
A02BC02
ATC
pantoprazole; systemic
2.1
48.8
1606
12502
H02AB06
ATC
prednisolone; systemic
1.9
46.4
1164
8195
TKE10
NOMESCO Finland
Puncture of prostate
5.8
46.4
86
153
L02BB06
ATC
darolutamide; oral
17.9
45.5
37
21
WF029
NOMESCO Finland
Radiotherapy of local residive tumor
7.3
44.6
66
93
L03AA02
ATC
filgrastim; parenteral
4.1
43.8
123
311
YX9AW, ,
NOMESCO Finland
9.6
43.4
51
54
UKC02
NOMESCO Finland
Cystoscopy
1.9
41.8
703
4306
H02AB07
ATC
prednisone; oral
2.3
41.6
358
1704
Z03.1
ICD-10 Finland
Observation for suspected malignant neoplasm
3.9
39.2
117
309
TNX00
NOMESCO Finland
Puncture and needle biopsy of soft tissue, unspecified region
5.7
38.1
71
127
KH1YT
NOMESCO Finland
Percutaneous implantation of endoprothesis with radiological guidance
9.2
37.8
46
51
WPA10
NOMESCO Finland
Proactive palliative care treatment plan
6.0
36.6
65
111
WF099
NOMESCO Finland
Other radiotherapy
9.0
36.4
45
51
R31
ICD-10 Finland
Unspecified haematuria
2.0
36.1
482
2707
308
Kela drug reimbursment
Alprostadil, sildenafil and combination product containing aviptadil and phentolamine
3.3
35.7
138
433
KEC00
NOMESCO Finland
Retropubic radical prostatectomy
3.6
34.8
119
345
KFC10
NOMESCO Finland
Bilateral orchiectomy
9.7
34.2
40
42
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
2.7
34.0
196
771
1CD04, ,
NOMESCO Finland
172.6
32.8
34
*
WVA20, ,
SPAT
3.3
32.4
124
387
YX9BD
NOMESCO Finland
Other extensive CT eamination for dose design of radiotherapy
7.2
32.3
48
68
N02BE01
ATC
paracetamol; systemic, rectal
2.3
32.1
1949
17159
SPAT1088
SPAT
Blood transfusion
7.3
31.4
46
64
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
6.4
31.3
52
83
JN2CG
NOMESCO Finland
Extensive MRI examination of lower part of abdoment with high intensity magnet
4.4
31.3
79
184
TKC22
NOMESCO Finland
Catheterisation instruction
3.0
31.2
146
513
A55
ICPC
General and Unspecified, Local injection/infiltration
6.3
30.9
52
84
N42.9
ICD-10 Finland
Disorder of prostate, unspecified
3.4
30.0
110
334
L95
ICPC
Osteoporosis
4.6
29.8
71
158
Z51.0
ICD-10 Finland
Radiotherapy session
4.7
29.7
70
154
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
1.7
29.6
888
6311
TKC10
NOMESCO Finland
Percutaneous puncture of bladder
3.9
29.4
88
233
5BX04, ,
NOMESCO Finland
40.7
29.0
36
9
L02BB01
ATC
flutamide; oral
10.8
28.7
31
29
KE1BG
NOMESCO Finland
MRI of prostate
4.0
28.6
81
206
A98
ICPC
Health maint/preventive medicine
2.6
27.4
2031
18432
PJD44
NOMESCO Finland
Excision of iliac lymph nodes
5.6
27.3
52
95
ZXC20
NOMESCO Finland
Use of chemical agents
3.5
26.9
93
272
TKC20
NOMESCO Finland
Catheterisation of bladder
2.1
26.7
275
1393
ECB20
NOMESCO Finland
Oral alveoplasty
4.9
26.5
59
124
KA3EB
NOMESCO Finland
Antegrade pyelography
6.5
26.5
43
67
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
1.9
26.0
379
2169
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
2.0
25.9
330
1805
KBV02
NOMESCO Finland
Cystoscopic insertion of stent into ureter
3.3
25.7
101
320
SPAT1203
SPAT
Injection therapy, other than intramuscular or subcutaneous
2.9
25.6
121
427
EB1BI
NOMESCO Finland
Cone beam imaging of teeth and jaws (1–2 quarters)
4.3
25.2
65
154
A28
ICPC
Limited function/disability NOS
1.7
25.2
544
3505
ZX020
NOMESCO Finland
HDR radiotherapy within tissue
9.8
25.0
29
30
ZX050
NOMESCO Finland
Stereotactic radiotherapy
4.9
24.4
54
113
KE1CG
NOMESCO Finland
Extensive MRI of prostate
4.3
23.1
59
139
KE1DG
NOMESCO Finland
Very extensive MRI of prostate
3.8
22.8
70
189
A50
ICPC
General and Unspecified, Medication/prescr/renewal
2.8
22.3
111
403
WB221
NOMESCO Finland
Demanding neoadjuvant hormone therapy of malignancy
8.0
22.2
30
38
G04BD12
ATC
mirabegron; oral
1.8
22.1
363
2150
R06AE07
ATC
cetirizine; oral
1.6
21.5
669
4706
C77.9
ICD-10 Finland
Secondary and unspecified malignant neoplasm: Lymph node, unspecified
24.5
20.9
29
12
166
Kela drug reimbursment
Dalteparin and tinzaparin (treatment for more than 6 months)
4.8
20.8
47
100
J01EA01
ATC
trimethoprim; systemic
1.8
20.6
356
2139
XX7JT
NOMESCO Finland
Somatostatin isotope ablative therapy
18.5
20.4
31
17
KH1AT
NOMESCO Finland
Urinary tract cathetrisation with ultrasound guidance
7.2
20.4
30
42
JN4CD
NOMESCO Finland
Very extensive body CT
2.5
20.2
136
575
OAB42
NOMESCO Finland
Guidance related to known health problem
5.9
20.1
36
62
B03XA02
ATC
darbepoetin alfa; parenteral
2.9
19.9
92
321
YG1BD
NOMESCO Finland
Extensive CT examination of thorax for dose design of radiotherapy
4.0
19.7
56
143
3036, ,
Kela drug reimbursment
17.9
19.6
30
17
1525, ,
Kela drug reimbursment
17.9
19.6
30
17
WVA30
NOMESCO Finland
Intramuscular and subcutaneous injection
6.0
18.2
32
54
SPAT1167
SPAT
Insertion of urinary catheter
2.3
18.2
137
609
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
2.3
18.1
146
668
Y78
ICPC
Malign neopl male genital other
15.4
18.0
29
19
J01MA12
ATC
levofloxacin; systemic
1.6
17.9
508
3471
KC1GB
NOMESCO Finland
Cystography with X-ray
3.4
17.8
65
197
R50.9
ICD-10 Finland
Fever, unspecified
1.7
17.7
384
2451
D70.82
ICD-10 Finland
Drug-induced neutropenia
4.1
17.7
49
123
WPB10
NOMESCO Finland
Making a convalescent care decision
6.4
17.6
29
46
KDV12
NOMESCO Finland
Urethroscopic internal urethrotomy
3.3
17.6
65
199
B01AB10
ATC
tinzaparin; parenteral
1.8
17.5
268
1548
WZB00
NOMESCO Finland
Telephone prescription or other care instructions
1.6
17.4
507
3483
Y50
ICPC
Male Genital, Medication/prescr/renewal
12.7
17.1
30
24
K52.0
ICD-10 Finland
Gastroenteritis and colitis due to radiation
6.4
17.1
28
44
NK6SN
NOMESCO Finland
Bone SPECT
17.5
16.9
26
15
G04BE03
ATC
sildenafil; oral
2.8
16.5
84
309
N02AJ06
ATC
codeine and paracetamol; systemic
1.5
16.4
860
6685
WPA15
NOMESCO Finland
Palliative care consultation with the patient and loved ones
5.4
16.4
32
60
U08
ICPC
Urinary retention
2.4
16.2
116
504
S50
ICPC
Skin, Medication/prescr/renewal
5.1
16.2
34
68
TQX05
NOMESCO Finland
Skin puncture, unspecified location
12.9
16.1
28
22
M49.5*C79.5
ICD-10 Finland
Metastatic fracture of vertebra
11.7
16.0
29
25
KE002
NOMESCO Finland
Radical radiotherapy of prostata and seminal vesicles
5.6
16.0
30
54
SAA03
NOMESCO Finland
Extended examination of mouth
1.5
15.9
672
4995
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
1.8
15.8
236
1351
YN1AD
NOMESCO Finland
CT examination of extremities for dose design of radiotherapy
17.3
15.6
24
14
C78.7
ICD-10 Finland
Secondary malignant neoplasm of liver and intrahepatic bile duct
2.6
15.6
90
354
Z3231
NOMESCO Finland
Registered nurse
1.5
15.5
622
4568
XX3AT
NOMESCO Finland
Other labeling with ultrasound guidance
5.2
15.3
31
60
A06AD11
ATC
lactulose; oral
1.6
15.2
389
2582
KA1AE
NOMESCO Finland
Kidney ultrasound examination
2.5
15.1
96
395
130
Kela drug reimbursment
Malignant tumour
0.4
14.8
89
1993
D64.9
ICD-10 Finland
Anaemia, unspecified
1.6
14.7
344
2232
EB1CI
NOMESCO Finland
Cone beam imaging of teeth and jaws (3-4 quarters)
3.9
14.6
43
113
J01DB01
ATC
cefalexin; oral
1.5
14.6
1688
15113
YG1AD
NOMESCO Finland
CT examination of thorax for dose design of radiotherapy
3.8
14.5
44
118
XX9AQ
NOMESCO Finland
Supplementary SPECT-CT or additional scan
10.9
14.5
27
25
5BA08, ,
NOMESCO Finland
6.6
14.5
23
35
TPH04
NOMESCO Finland
Cathetrisation of vein
1.5
14.4
543
3925
JN2DM
NOMESCO Finland
Lower part of abdomen very extensive MRI examination with Tesla magnet
10.5
14.2
27
26
XX2RW, ,
NOMESCO Finland
3.6
14.1
46
130
R86.1
ICD-10 Finland
Abnormal findings in specimens from male genital organs, abnormal level of hormones
5.5
14.0
27
50
U28
ICPC
Limited function/disability (U)
3.2
13.6
53
168
EB1AI
NOMESCO Finland
Cone beam imaging of teeth and jaws (one quarter)
3.6
13.5
44
124
N30.4
ICD-10 Finland
Irradiation cystitis
9.7
13.2
26
27
JN3BD
NOMESCO Finland
Extensive abdominal CT
1.7
13.1
234
1410
8000/3-C61.9
ICD-O-3
Neoplasm, malignant of prostate gland
17.4
12.5
19
11
N39.3
ICD-10 Finland
Stress incontinence
3.1
12.2
49
158
EBA10
NOMESCO Finland
Operative extraction of tooth
1.8
12.2
190
1100
A07EA02
ATC
hydrocortisone; rectal
2.9
12.1
55
191
D63.0
ICD-10 Finland
Anaemia in neoplastic disease
26.8
12.0
16
6
C03CA01
ATC
furosemide; systemic
1.4
11.8
854
6919
M01AE01
ATC
ibuprofen; systemic, rectal
1.5
11.7
1704
15494
ZX100
NOMESCO Finland
Oral
3.0
11.6
50
169
NE1AA
NOMESCO Finland
Pelvis X-ray examination
1.8
11.5
194
1150
C79.1
ICD-10 Finland
Secondary malignant neoplasm of bladder and other and unspecified urinary organs
120.6
11.4
12
*
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
1.6
11.4
275
1792
SPAT1154
SPAT
Insertion or removal of subcutaneous medicine capsule
9.7
11.2
22
23
K62.5
ICD-10 Finland
Haemorrhage of anus and rectum
1.9
11.2
138
742
KE1JR
NOMESCO Finland
Extensive PET-CT of prostatic metabolism
20.1
11.1
16
8
ZXF99
NOMESCO Finland
Other r3eason to interrupt procedure
5.0
11.0
23
46
WC205
NOMESCO Finland
Simple therapy of local tumor recidive with hormone
43.5
10.9
13
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
1.4
10.9
1194
10282
SPAT1109
SPAT
Analgesia with portable analgesic pump
3.9
10.8
31
80
NA3DG
NOMESCO Finland
Lumbar spine very extensive MRI examination with high intensity magnet
4.3
10.8
27
63
B01AB05
ATC
enoxaparin; parenteral
1.4
10.7
688
5445
NF3AA
NOMESCO Finland
Femur X-ray examination
2.6
10.7
59
228
EDW99
NOMESCO Finland
Other operation on mandible
13.0
10.6
18
14
-55
ICPC
Local injection/infiltration
4.2
10.6
28
68
WPA44, ,
SPAT
4.5
10.5
25
56
WPA13
NOMESCO Finland
Palliative consultation
4.7
10.5
24
52
U04
ICPC
Incontinence urine
1.9
10.3
136
749
M05BA08
ATC
zoledronic acid; parenteral
23.5
10.2
14
6
L28
ICPC
Limited function/disability (L)
1.4
9.9
443
3282
WX408
NOMESCO Finland
General anesthesy, balanced
1.4
9.9
558
4307
A49.8
ICD-10 Finland
Other bacterial infections of unspecified site
3.5
9.9
33
95
A04AA55
ATC
palonosetron, combinations; systemic
2.8
9.9
47
168
C78.0
ICD-10 Finland
Secondary malignant neoplasm of lung
2.5
9.8
62
256
Z08.1
ICD-10 Finland
Follow-up examination after radiotherapy for malignant neoplasm
4.7
9.8
22
47
WPA43, ,
SPAT
5.3
9.6
19
36
XX1AD
NOMESCO Finland
Other CT-examination
3.7
9.4
29
79
U50
ICPC
Urological, Medication/prescr/renewal
21.8
9.3
13
6
U13
ICPC
Bladder symptom/complaint other
2.3
9.3
66
287
KCW02
NOMESCO Finland
Lavation of bladder for coagulated blood
2.6
9.3
54
214
JN2BG
NOMESCO Finland
MRI examination of lower part of abdoment with high intensity magnet
4.9
9.3
20
41
KCW96
NOMESCO Finland
Other operations on bladder
3.7
8.7
27
74
JN3AD
NOMESCO Finland
Abdominal CT examination
1.5
8.7
311
2204
K10.25
ICD-10 Finland
Sequences of jawbones
4.6
8.6
20
44
XZZ00
NOMESCO Finland
Active surveillance of a diagnosed cancer
2.5
8.6
51
205
K10.20
ICD-10 Finland
Osteomyelitis (neonatal) of jaw (acute)(chronic)(suppurative)
11.6
8.6
15
13
JN3CD
NOMESCO Finland
Abdominal CT examination both without and with contrast
1.9
8.5
102
545
SPAT1245
SPAT
Provision of support and information to patient’s family members
1.8
8.5
121
683
G04BD08
ATC
solifenacin; oral
1.7
8.5
156
948
WX110
NOMESCO Finland
Infiltration anesthesia
1.3
8.4
1327
11840
C61, C798,
ICD-10 Finland
+∞
8.3
8
*
K62.8
ICD-10 Finland
Other specified diseases of anus and rectum
3.5
8.2
27
77
Y99
ICPC
Genital disease male other
7.1
8.2
19
27
SPAT1255
SPAT
Intravenous administration of medicine
1.6
8.1
170
1069
SAA02
NOMESCO Finland
Basic examination of mouth
1.3
8.1
1077
9371
HB000
NOMESCO Finland
Profylactic radiotherapy of mammary gland
8.9
8.0
16
18
U29
ICPC
Urinary symptom/complaint other
2.1
8.0
77
380
WPA45
NOMESCO Finland
Continuous drug infusion in palliative care
7.3
8.0
18
25
L01XX11
ATC
estramustine; systemic
7.3
8.0
18
25
-50
ICPC
Medication/prescr/renewal
1.9
7.9
96
515
KDW96
NOMESCO Finland
Other operations on urethra
6.6
7.9
19
29
R39.1
ICD-10 Finland
Other difficulties with micturition
1.8
7.8
107
597
U06
ICPC
Haematuria
1.9
7.7
99
541
WPA16
NOMESCO Finland
Extensive demanding palliative symptom assessment and treatment
6.4
7.7
19
30
XF600
NOMESCO Finland
Bloodpressure measurement
1.7
7.7
147
903
R60.0
ICD-10 Finland
Localized oedema
1.5
7.6
280
1993
A29
ICPC
General symptom/complaint other
1.5
7.6
294
2113
ZXF10
NOMESCO Finland
Interruption caused by technical failure of equipment
8.1
7.6
16
20
G04BE01
ATC
alprostadil; parenteral, urethral
1.9
7.5
87
461
KED22
NOMESCO Finland
Transurethral resection of prostate
1.5
7.4
275
1961
B02AA02
ATC
tranexamic acid; systemic
1.7
7.3
125
745
C61, C795,
ICD-10 Finland
+∞
7.3
7
*
K02.1
ICD-10 Finland
Caries of dentine
1.3
7.3
985
8542
YN1BD
NOMESCO Finland
Extensive CT examination of extremities for dose design of radiotherapy
9.4
7.3
14
15
KCV22
NOMESCO Finland
Transluminal endoscopic evacuation of blood clots from bladder
4.5
7.2
17
38
WGA10
NOMESCO Finland
Measurement of pain intensity
20.1
7.1
10
5
N30.0
ICD-10 Finland
Acute cystitis
1.6
7.1
189
1258
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
1.4
7.1
335
2499
N02AA01
ATC
morphine; systemic, rectal
2.1
7.1
64
310
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
1.4
7.0
271
1947
C79.30
ICD-10 Finland
Secondary malignant tumor of the cerebrum
2.9
7.0
32
113
KDE20
NOMESCO Finland
Removal of foreign body from urethra
2.4
6.9
44
184
EBA15
NOMESCO Finland
Extraction of multiple teeth
1.7
6.8
109
639
U71
ICPC
Cystitis/urinary infection other
2.2
6.8
55
255
SPAT1263
SPAT
Sampling
1.3
6.7
787
6682
TQW40, ,
SPAT
0.5
6.7
82
1450
2AE02, ,
NOMESCO Finland
22.6
6.7
9
*
WB211
NOMESCO Finland
Neoadjuvant hormone therapy of malignancy
22.6
6.7
9
*
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
1.3
6.6
511
4109
J01CR02
ATC
amoxicillin and beta-lactamase inhibitor; systemic
1.3
6.6
904
7822
R5110, ,
SPAT
1.5
6.5
177
1184
SPAT1168
SPAT
Catheterisation training
3.1
6.5
26
85
N02AA03
ATC
hydromorphone; systemic, rectal
5.7
6.4
17
30
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
1.5
6.4
182
1229
JR2PR, ,
NOMESCO Finland
70.1
6.4
7
*
WX290
NOMESCO Finland
Other blockage of nerve
1.3
6.4
687
5763
M84.4
ICD-10 Finland
Pathological fracture, not elsewhere classified
7.4
6.4
14
19
OAB77
NOMESCO Finland
Discussion on exercise habits and instruction concerning use of sports and fitness services
11.0
6.3
11
10
WB201
NOMESCO Finland
Simple neoadjuvant hormone therapy of malignancy
9.3
6.3
12
13
L01XK01
ATC
olaparib; oral
+∞
6.3
6
*
XX7KT
NOMESCO Finland
Radiosamarium therapy
+∞
6.3
6
*
JN5AN
NOMESCO Finland
Total body isotope imaging
26.7
6.2
8
*
YN7VG
NOMESCO Finland
MRI examination of spine with high intesinty magnet for dose design of radiotherapy
26.7
6.2
8
*
EFA20
NOMESCO Finland
Decortication of jaws
26.7
6.2
8
*
T88.7
ICD-10 Finland
Unspecified adverse effect of drug or medicament
2.8
6.2
30
109
SPAT1110
SPAT
Measurement of pain intensity
3.5
6.2
20
57
C77.1
ICD-10 Finland
Secondary and unspecified malignant neoplasm: Intrathoracic lymph nodes
4.1
6.1
16
39
EDA10
NOMESCO Finland
Biopsy of mandible
8.6
6.1
12
14
XKW99
NOMESCO Finland
Other physiological examination of urinary or male genital system
2.2
6.0
49
228
JAP01
NOMESCO Finland
Laparoscopic freeing of adhesions in the peritoneal cavity
3.2
6.0
23
73
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
1323
2763
10.72
307.65
2.9
2.1
3.00
13.42
nmol/l
294.24
1056
2406
1371
6893
3.69
188.13
11.1
3.6
2.34
2.33
mmol/l
0.49
1323
6182
1830
11273
5.00
182.90
17.1
7.3
10.26
13.68
umol/l
40.95
1812
10827
2081
15315
9.94
140.54
22.0
9.2
101.87
82.13
u/l
18.30
2061
14598
1883
13091
4.33
129.60
6.4
4.9
353.40
588.94
e6/l
0.22
35
230
1700
11152
3.43
126.56
13.6
8.5
1.20
1.20
mmol/l
2.64
1493
9620
2084
15892
9.04
121.31
21.6
6.1
32.94
2.78
ug/l
18.31
2033
14252
1692
11357
3.23
114.96
18.9
9.5
4.26
4.54
e9/l
4.90
1546
9728
1766
12797
3.05
91.77
10.2
5.1
20.41
22.27
%
5.16
1379
6981
1409
9265
2.49
86.94
5.4
3.6
1.93
0.77
ug/l
24.50
1170
6752
710
3442
2.58
85.87
6.8
4.4
269.56
241.66
u/l
3.23
688
3264
1485
10061
2.51
84.82
10.3
7.7
1.21
1.20
mmol/l
8.06
1431
9304
1231
7890
2.30
76.50
5.0
3.9
127.03
113.49
e6/l
0.15
1051
6268
794
4242
2.38
75.90
5.9
3.4
2.46
2.45
mmol/l
1.53
753
3782
1436
10058
2.27
68.67
7.1
5.9
33.74
34.39
g/l
4.03
1376
9412
1074
6765
2.16
66.36
4.7
3.8
0.42
0.45
e6/l
0.12
902
5187
1241
8388
2.12
62.34
5.7
4.4
142.21
110.39
e6/l
0.37
1055
6390
931
5656
2.13
61.95
3.5
2.9
2.79
2.90
e6/l
0.23
869
5177
2083
17791
5.36
61.66
30.4
21.8
32.86
30.86
mg/l
1.90
1948
15371
676
3951
2.03
47.03
4.4
3.7
0.68
0.63
e6/l
0.20
416
2160
2091
18581
4.53
43.83
24.1
13.9
23.38
27.30
u/l
9.51
2066
17927
2112
18913
5.52
43.53
49.0
32.6
230.45
224.96
e9/l
3.43
2086
18470
2112
18913
5.52
43.53
48.8
32.4
92.46
92.16
fl
2.20
2099
18670
2112
18913
5.52
43.53
48.9
32.5
4.14
4.46
e12/l
121.55
2078
18387
2112
18914
5.52
43.51
49.3
33.3
37.64
40.36
%
99.83
2098
18659
2112
18915
5.51
43.48
49.2
32.8
124.60
135.66
g/l
158.31
2098
18674
2112
18915
5.51
43.48
49.0
32.6
6.76
7.12
e9/l
7.14
2081
18394
2109
18874
5.31
43.34
46.2
29.4
88.48
93.76
umol/l
9.66
2093
18655
2096
18719
4.60
42.23
34.8
27.3
4.02
4.04
mmol/l
2.99
2078
18383
1310
9756
1.87
42.04
3.6
3.2
—
—
estimate
—
0
0
2093
18702
4.44
41.53
34.1
27.0
139.28
139.62
mmol/l
7.79
2074
18384
1624
13066
1.97
39.87
5.4
6.1
6.91
7.00
mmol/l
1.04
1581
12562
1504
11831
1.89
39.13
17.3
21.5
1.28
1.39
inr
12.19
1286
10143
678
4249
1.87
36.64
4.3
3.5
0.90
0.89
e6/l
0.02
421
2460
353
1766
2.19
35.98
7.3
4.7
1.21
1.21
mmol/l
0.11
331
1552
1967
17215
2.54
35.92
36.6
21.7
75.71
72.70
ml/min/173m2
10.64
1916
16195
922
6410
1.76
34.83
6.0
3.5
34.61
41.46
u/l
1.29
889
6015
1351
10478
1.77
34.56
6.6
6.3
1.57
1.85
e9/l
3.26
1173
9059
699
4535
1.80
33.08
2.0
2.0
—
—
—
0
0
1351
10602
1.73
31.86
6.6
6.3
0.18
0.21
e9/l
9.88
1148
9103
789
5442
1.71
29.30
3.2
2.8
—
—
—
0
0
658
4420
1.70
26.35
2.5
3.0
12.06
12.39
umol/l
0.56
624
4125
1120
8632
1.62
25.87
19.7
13.6
0.01
0.00
e9/l
0.21
939
7008
869
6350
1.62
24.63
2.2
2.4
3.04
2.85
mg/l
1.63
770
5473
623
4193
1.68
24.43
2.3
3.0
2.06
2.20
g/l
9.27
577
3889
590
3942
1.68
23.66
2.3
3.0
23.23
22.70
%
0.40
555
3677
259
1396
1.97
21.00
1.8
1.9
2.63
2.68
ug/l
0.01
231
1226
602
4159
1.62
20.70
3.2
3.4
0.82
0.82
mmol/l
0.39
586
3931
1272
10466
1.52
19.49
4.4
3.9
0.04
0.16
estimate
0.38
331
2100
1249
10284
1.51
18.71
4.4
3.9
0.00
0.00
estimate
0.50
344
2296
501
3404
1.61
18.08
1.9
1.9
—
—
—
0
0
730
5472
1.50
16.75
5.5
4.8
86.34
78.83
%
12.88
721
5387
462
3143
1.60
16.39
1.9
2.0
—
—
—
0
0
1247
10420
1.46
16.26
4.4
3.9
0.01
3.60
estimate
1.77
352
2318
1032
8343
1.45
15.86
3.6
3.5
1674.26
1857.29
ng/l
0.75
953
7465
403
2685
1.62
15.51
3.1
4.5
18.04
27.42
ug/l
0.57
327
2293
690
5185
1.49
15.35
4.1
3.6
0.02
0.03
estimate
0.21
251
1761
1028
8375
1.43
14.76
2.8
3.2
444.30
191.66
ug/l
17.01
950
7684
570
7539
0.67
14.64
2.0
2.0
1.47
1.27
mmol/l
3.75
457
6106
1314
11204
1.44
14.61
3.8
3.6
58.41
64.26
u/l
0.91
1216
10304
231
1373
1.76
13.58
1.6
1.5
—
—
—
0
0
186
1055
1.83
12.77
2.0
2.0
—
—
—
0
0
107
508
2.16
12.19
1.9
4.0
2.61
1.71
%
1.18
93
448
1000
8309
1.38
11.83
2.3
2.2
—
—
—
0
0
677
8449
0.71
11.75
3.5
3.7
7.43
8.08
mmol/l
4.95
546
7037
265
1707
1.63
11.50
1.8
1.8
—
—
—
0
0
169
983
1.78
10.68
1.9
1.8
—
—
—
0
0
632
4945
1.39
10.46
3.5
3.0
0.05
0.06
0.14
22
154
912
7633
1.34
9.60
4.6
4.0
0.01
0.01
estimate
0.04
288
1939
117
628
1.91
9.57
3.6
3.7
1.93
1.83
index
0.08
60
353
823
6795
1.34
9.47
2.7
2.9
53.27
73.23
u/l
1.04
782
6328
710
8587
0.74
9.30
4.3
4.5
8.72
10.40
mg/mmol
0.51
470
5889
1043
8936
1.32
9.19
4.4
4.6
74.08
67.04
ng/l
0.10
914
7451
184
1152
1.65
8.91
4.4
3.6
1.02
1.02
ratio
0.91
172
1058
344
2507
1.44
8.32
3.4
3.1
6.87
10.89
umol/l
5.30
313
2280
256
1765
1.51
8.19
1.5
1.7
—
—
—
0
0
69
325
2.16
8.11
2.1
1.2
—
—
—
0
0
737
6091
1.32
8.10
4.4
4.1
0.00
0.00
estimate
0.08
293
1963
70
342
2.08
7.52
2.1
4.2
63.55
58.52
%
1.18
58
284
316
2335
1.41
7.03
3.1
3.1
219.46
236.16
ng/l
0.24
296
2168
833
7110
1.28
6.88
2.0
1.8
17.26
18.91
nmol/l
2.78
730
6028
127
774
1.68
6.86
1.3
1.3
—
—
—
0
0
114
692
1.68
6.27
1.2
1.6
—
—
—
0
0
371
2897
1.34
5.82
3.1
2.6
67.65
67.14
e9/l
0.11
282
2171
569
4722
1.28
5.68
4.1
4.6
301.89
652.62
ng/l
1.17
509
4261
257
1929
1.38
5.19
2.4
2.6
31.04
41.74
u/l
2.02
213
1642
432
3504
1.29
5.11
5.0
7.1
1.03
1.03
mmol/l
0.05
410
3314
355
2811
1.31
5.02
3.4
4.1
1.41
1.67
mmol/l
0.68
291
2425
94
585
1.63
4.77
3.8
3.7
7.16
7.67
mmol/l
1.23
94
566
177
2426
0.71
4.71
1.2
1.3
14.08
14.63
u/ml
0.03
49
815
120
1765
0.66
4.66
1.8
1.8
1.55
1.74
%
2.50
100
1441
354
2830
1.30
4.65
5.7
7.8
11.17
11.60
mmol/l
0.48
335
2701
358
2873
1.29
4.57
3.4
4.1
5.61
5.80
kpa
3.82
351
2797
79
487
1.65
4.20
1.6
1.3
—
—
—
0
0
79
487
1.65
4.20
1.6
1.3
—
—
—
0
0
30
135
2.24
4.09
1.7
3.1
1.98
1.00
%
2.00
30
135
232
2976
0.75
4.02
1.5
1.6
2.61
3.03
g/l
1.92
127
1810
1469
13769
1.21
4.02
44.0
28.5
330.04
332.90
g/l
26.96
1463
13690
105
701
1.52
4.00
1.3
1.6
—
—
—
0
0
151
1090
1.41
3.88
2.3
2.2
0.00
0.97
estimate
0.52
40
267
57
333
1.73
3.73
1.4
1.6
—
—
—
0
0
50
283
1.78
3.65
1.4
1.5
—
—
—
0
0
50
288
1.75
3.46
1.4
1.5
—
—
—
0
0
553
6321
0.83
3.42
2.8
3.4
372.14
377.04
umol/l
0.43
466
5458
10
297
0.33
3.30
1.0
1.1
—
—
—
0
0
28
135
2.09
3.28
1.2
1.9
—
—
—
0
0
28
135
2.09
3.28
1.2
1.9
—
—
—
0
0
28
135
2.09
3.28
1.2
1.9
—
—
—
0
0
28
135
2.09
3.28
1.2
1.9
—
—
—
0
0
50
293
1.72
3.28
1.4
1.5
—
—
—
0
0
207
2605
0.77
3.11
1.1
1.3
27.72
37.95
iu/ml
0.80
56
712
5
182
0.27
3.11
1.0
1.1
—
15.67
—
0
22
1181
12605
0.86
2.97
3.3
3.4
15.12
15.03
pmol/l
0.51
1057
11210
5
176
0.28
2.97
1.0
1.1
—
1.44
—
0
13
32
169
1.91
2.95
1.2
1.6
—
—
—
0
0
119
1607
0.73
2.94
2.2
2.7
9.89
10.88
g/l
1.91
104
1482
73
487
1.52
2.88
1.4
1.7
—
—
—
0
0
254
3086
0.80
2.85
1.2
1.2
0.88
2.24
u/ml
5.58
48
764
97
687
1.43
2.84
2.8
2.3
120.75
129.40
g/l
2.64
77
529
82
1165
0.69
2.75
2.7
2.6
—
—
—
0
0
33
181
1.84
2.74
1.3
1.5
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
148
1136
1.33
2.67
2.7
2.8
0.36
0.32
iu/ml
0.73
89
610
1811
17522
1.20
2.63
5.3
6.1
6.25
6.24
mmol/l
0.16
1621
15791
84
589
1.44
2.62
1.4
1.4
—
—
—
0
0
0
68
0.00
2.60
0.0
1.1
—
—
—
0
0
46
283
1.64
2.58
1.4
1.5
—
—
—
0
0
38
222
1.72
2.58
1.3
1.6
—
—
—
0
0
851
7803
1.15
2.55
2.1
2.3
82.11
76.62
nmol/l
5.87
760
6800
468
4103
1.18
2.53
1.5
1.7
2.33
1.77
mg/l
1.49
390
3297
46
285
1.63
2.52
1.4
1.5
—
—
—
0
0
46
285
1.63
2.52
1.4
1.5
—
—
—
0
0
1792
17353
1.19
2.41
7.1
7.9
41.21
41.00
mmol/mol
0.25
1645
15992
25
450
0.55
2.36
1.3
1.3
—
—
—
0
0
127
1637
0.76
2.33
1.6
1.4
—
—
—
0
0
299
2542
1.20
2.29
3.9
3.9
—
—
—
0
0
62
426
1.47
2.19
1.2
1.3
—
—
—
0
0
43
273
1.59
2.18
3.2
1.6
44.94
35.47
ng/l
0.25
43
273
186
1514
1.25
2.17
1.4
1.7
1.89
1.51
g/l
3.89
150
1314
8
199
0.40
2.16
1.0
1.0
883.88
607.62
ng/l
—
8
131
8
199
0.40
2.16
1.1
1.0
537.13
319.40
ng/l
—
8
136
8
199
0.40
2.16
1.0
1.0
46.50
42.64
ng/l
—
8
132
36
571
0.62
2.12
1.6
1.5
0.01
17.29
iu/ml
—
5
126
0
56
0.00
2.06
0.0
1.0
—
26.38
—
0
15
222
2635
0.82
2.01
9.4
8.5
—
—
—
0
0
205
1703
1.23
2.00
3.1
3.9
1.73
1.82
mmol/l
0.13
142
1231
159
1949
0.80
1.97
7.3
10.1
93.54
93.85
%
0.20
159
1941
53
757
0.69
1.91
1.2
1.6
0.23
0.33
mg/l
1.00
29
372
63
453
1.40
1.80
1.2
1.5
—
—
—
0
0
20
350
0.57
1.78
1.3
1.3
—
—
—
0
0
31
192
1.62
1.78
1.2
1.5
—
—
—
0
0
767
7116
1.12
1.77
2.6
2.3
225.66
253.11
u/l
0.33
730
6719
31
482
0.64
1.73
1.3
1.4
—
—
—
0
0
27
164
1.65
1.68
1.3
1.6
—
—
—
0
0
28
172
1.64
1.67
1.4
1.8
1.00
1.15
u/field
0.12
12
94
51
360
1.43
1.64
1.4
1.6
—
—
—
0
0
1064
10083
1.11
1.63
2.2
2.3
89.64
91.06
pmol/l
0.45
663
5949
32
205
1.57
1.62
3.4
3.7
13.39
10.67
index
0.99
23
123
67
889
0.75
1.59
1.4
1.3
318.11
349.52
u/ml
0.08
62
812
36
239
1.51
1.57
1.4
1.5
—
—
—
0
0
232
2001
1.18
1.56
3.3
4.1
4.90
5.11
kpa
3.40
218
1917
1458
14062
1.11
1.56
3.5
4.5
19.82
13.73
mm/h
19.91
1341
13025
466
4228
1.13
1.55
2.3
2.0
30.07
30.19
s
0.16
453
4118
21
347
0.60
1.54
1.0
1.1
—
2.47
—
0
20
5
15
3.34
1.52
1.2
1.3
18.80
11.47
u/l
—
5
15
519
4746
1.12
1.52
2.2
1.9
417.22
31154251.44
pmol/l
3.68
436
3900
282
3197
0.86
1.51
5.9
8.0
94.74
95.27
%
0.51
270
3085
77
593
1.31
1.47
1.2
1.5
—
—
—
0
0
48
343
1.41
1.47
5.9
28.3
7.40
7.45
mmol/l
0.04
41
294
18
102
1.77
1.45
1.3
2.1
—
—
—
0
0
18
102
1.77
1.45
1.3
2.1
—
—
—
0
0
69
525
1.32
1.44
1.2
1.5
—
—
—
0
0
17
95
1.80
1.43
2.1
2.7
9.86
9.95
kpa
0.06
17
95
17
95
1.80
1.43
2.1
2.7
4.57
4.90
kpa
0.66
17
95
27
409
0.66
1.38
1.3
1.4
20.52
1088.53
e6/l
2.05
21
333
267
2354
1.15
1.38
2.8
3.3
4.10
4.50
kpa
2.96
257
2288
18
104
1.74
1.37
1.3
2.0
—
—
—
0
0
313
3494
0.88
1.35
5.7
7.9
11.77
11.86
kpa
0.11
301
3370
313
3493
0.88
1.34
5.7
7.9
4.85
5.05
kpa
3.72
300
3365
17
98
1.74
1.31
1.4
1.4
—
—
—
0
0
27
403
0.67
1.30
1.1
1.4
7.79
31.33
e6/l
0.86
19
311
54
714
0.75
1.30
1.6
2.3
51.74
121.14
ug/min
2.74
28
419
8
34
2.36
1.29
1.3
1.3
—
—
—
0
0
57
746
0.76
1.28
1.9
1.8
46.40
46.17
nmol/l
0.03
57
705
67
519
1.30
1.27
1.2
1.5
—
—
—
0
0
57
433
1.32
1.24
5.1
6.3
13.26
11.88
mg/l
1.11
51
408
14
238
0.59
1.19
1.3
2.2
754.00
656.28
ml
—
6
141
50
658
0.75
1.18
1.2
1.6
2.76
6.83
iu/ml
—
8
155
40
543
0.73
1.17
2.0
1.9
3.49
3.21
mmol/l
0.59
30
415
30
427
0.70
1.16
1.1
1.2
3.18
4.00
u/ml
—
6
43
144
1679
0.85
1.14
2.4
2.4
154.76
188.29
ug/g
0.67
114
1353
161
1856
0.86
1.11
5.0
7.0
23.93
24.28
mmol/l
0.42
155
1778
122
1034
1.19
1.07
2.9
4.3
24.49
24.67
mmol/l
0.31
109
950
43
565
0.76
1.03
1.6
1.6
31.82
31.22
g/l
0.15
36
502
22
146
1.51
1.03
1.2
1.4
69.50
155.06
pmol/l
3.01
22
146
84
690
1.23
1.02
1.3
1.6
—
—
—
0
0
33
239
1.39
1.00
1.2
1.6
—
—
—
0
0
33
239
1.39
1.00
1.2
1.6
—
—
—
0
0
33
239
1.39
1.00
1.2
1.6
—
—
—
0
0
204
1811
1.14
1.00
5.1
3.0
60.21
59.69
ml/min/173m2
0.08
94
812
84
692
1.22
1.00
1.9
2.3
4.10
3.67
g/l
1.29
79
657
67
828
0.80
1.00
2.3
2.2
3.78
3.53
ratio
0.86
53
696
16
99
1.62
1.00
1.3
1.4
2.25
3.36
u/field
—
8
69
37
275
1.35
0.97
1.2
1.7
—
—
—
0
0
200
1778
1.14
0.97
3.2
3.5
116.82
128.54
g/l
9.93
195
1722
19
124
1.54
0.96
1.3
2.3
123.35
156.53
ng/l
0.53
19
124
70
854
0.81
0.94
1.8
1.7
38.53
36.99
u/l
0.27
59
723
57
711
0.80
0.94
3.1
2.7
1.87
1.87
mg/l
0.00
49
629
38
286
1.33
0.93
1.2
1.7
—
—
—
0
0
275
2500
1.11
0.93
3.7
2.8
64.80
65.76
g/l
1.36
243
2291
318
3463
0.90
0.92
5.6
7.9
0.63
0.79
mmol/l
0.27
253
2820
85
1013
0.83
0.91
1.8
3.6
2.78
2.87
ratio
0.02
49
606
9
152
0.59
0.88
1.0
1.1
—
—
—
0
0
178
1586
1.13
0.85
2.8
4.9
117.15
111.06
ng/l
0.23
157
1374
38
491
0.77
0.85
1.2
1.3
—
265.00
—
0
16
474
4449
1.08
0.83
2.0
1.8
1180.93
1144.46
nmol/l
0.33
363
3367
6
114
0.53
0.83
2.0
1.6
326.50
358.30
mu/l
—
6
84
155
1373
1.14
0.82
1.1
1.2
—
—
—
0
0
114
989
1.16
0.81
3.0
3.8
209.09
5256.78
u/ml
1.12
97
858
35
452
0.77
0.79
1.2
1.3
—
—
—
0
0
6
33
1.82
0.79
1.2
1.2
—
—
—
0
0
0
25
0.00
0.79
0.0
5.2
—
—
—
0
0
0
25
0.00
0.79
0.0
1.0
—
—
—
0
0
26
190
1.37
0.79
1.5
1.5
—
—
—
0
0
7
125
0.56
0.77
1.1
1.2
—
—
—
0
0
96
1112
0.86
0.77
2.2
3.7
91.71
62.94
mg/l
0.25
81
943
43
538
0.80
0.76
1.0
1.0
—
—
—
0
0
15
221
0.68
0.76
1.5
1.7
23.40
28.67
u/ml
—
5
45
11
67
1.65
0.75
5.8
5.2
13.71
13.43
%
0.51
11
67
229
2493
0.91
0.69
2.6
2.4
5.11
8.25
ug/l
4.93
204
2217
49
596
0.82
0.69
2.0
1.8
130.71
200.54
pmol/l
3.31
35
550
9
59
1.53
0.68
1.2
1.4
1.16
1.17
mmol/l
—
9
59
41
329
1.25
0.68
2.1
2.1
29.67
22.61
mg/l
0.34
18
113
97
1109
0.87
0.67
2.2
3.7
158.69
57.37
mg/l
0.40
83
946
48
393
1.23
0.67
1.1
1.2
—
—
—
0
0
25
188
1.33
0.66
1.5
1.5
—
—
—
0
0
19
137
1.39
0.64
1.5
1.5
—
—
—
0
0
19
137
1.39
0.64
1.5
1.6
—
—
—
0
0
48
396
1.22
0.63
1.1
1.2
—
—
—
0
0
6
103
0.58
0.62
1.0
1.1
—
—
—
0
0
52
620
0.83
0.62
1.4
1.6
26414.66
15755.26
e6/l
0.45
38
432
166
1821
0.90
0.60
7.0
9.8
23.77
24.09
mmol/l
0.67
161
1792
61
518
1.18
0.60
3.3
5.4
134.29
4784.09
iu/ml
—
7
87
0
21
0.00
0.60
0.0
1.0
—
1.50
—
0
11
36
443
0.81
0.59
1.3
1.3
0.98
0.81
nmol/l
0.87
28
370
188
1725
1.10
0.59
2.5
2.5
382.84
381.97
nmol/l
0.01
182
1595
0
23
0.00
0.58
0.0
1.1
—
—
—
0
0
0
23
0.00
0.58
0.0
1.0
—
—
—
0
0
19
140
1.36
0.58
1.5
1.7
97.74
99.67
umol/l
0.06
19
140
10
149
0.67
0.56
1.2
1.2
—
—
—
0
0
17
229
0.74
0.56
1.5
1.3
16.25
6.28
u/ml
—
8
110
51
601
0.84
0.55
1.1
1.2
83.61
98.11
u/ml
0.17
16
180
284
2663
1.08
0.54
4.7
5.5
32.40
32.51
%
0.06
187
1737
16
215
0.74
0.52
1.1
1.3
—
—
—
0
0
110
1221
0.90
0.52
1.8
2.6
4.03
3.76
g/l
0.50
91
1119
31
381
0.81
0.52
2.1
2.6
-0.37
0.13
mmol/l
0.28
26
370
6
99
0.60
0.52
1.3
1.2
—
—
—
0
0
6
99
0.60
0.52
1.3
1.2
—
—
—
0
0
12
168
0.71
0.50
2.6
3.3
—
—
—
0
0
60
690
0.87
0.49
1.3
1.4
—
—
—
0
0
14
190
0.74
0.49
1.1
1.2
—
—
—
0
0
7
46
1.52
0.48
1.4
1.5
4729.14
653.59
nmol/24h
—
7
46
111
1224
0.90
0.48
1.8
2.6
8.32
7.29
g/l
3.86
92
1121
10
143
0.70
0.47
1.2
1.2
—
82.63
—
0
11
10
143
0.70
0.47
2.8
2.4
158.60
242.65
e6/l
—
10
132
111
1223
0.90
0.47
1.8
2.6
3.94
4.10
g/l
1.48
93
1122
50
580
0.86
0.47
1.4
1.6
—
—
—
0
0
10
68
1.47
0.47
2.0
2.7
4.60
529.34
ug/l
—
10
68
83
741
1.12
0.46
3.7
3.7
4.43
4.32
pmol/l
0.36
77
654
7
51
1.37
0.44
1.9
2.2
—
—
—
0
0
17
130
1.31
0.44
1.9
2.0
—
—
—
0
0
1589
16088
0.95
0.43
4.0
4.5
2.09
2.09
mu/l
0.07
1411
14417
9
129
0.70
0.43
3.7
1.9
—
—
—
0
0
0
15
0.00
0.41
0.0
1.3
—
—
—
0
0
5
34
1.47
0.40
1.0
1.2
—
—
—
0
0
18
227
0.79
0.40
1.0
1.1
—
7.20
—
0
5
10
71
1.41
0.39
1.2
1.8
20.66
13.86
nmol/l
—
10
65
0
19
0.00
0.39
0.0
1.9
—
—
—
0
0
268
2546
1.06
0.38
5.3
8.1
1.34
1.39
mmol/l
0.33
262
2500
19
236
0.80
0.38
1.4
1.3
4.00
3.54
u/ml
—
5
87
106
1153
0.92
0.37
2.5
2.5
18.44
18.21
au/ml
0.01
12
76
9
68
1.32
0.37
1.0
1.3
—
—
—
0
0
8
112
0.71
0.37
1.4
1.8
10.75
14.66
nmol/l
—
8
100
12
157
0.76
0.35
1.3
1.2
90.75
92.06
%
0.06
12
144
13
167
0.78
0.34
1.0
1.0
—
—
—
0
0
30
256
1.17
0.33
1.3
1.5
—
—
—
0
0
39
444
0.88
0.32
2.3
1.6
—
—
—
0
0
52
465
1.12
0.31
3.7
3.7
36.90
32.95
mg/l
0.34
42
333
53
475
1.12
0.31
1.1
1.2
—
—
—
0
0
56
621
0.90
0.31
1.4
1.5
274.38
245.23
ug/g
0.48
39
420
7
53
1.32
0.30
1.3
1.2
—
—
—
0
0
7
53
1.32
0.30
1.9
2.2
—
—
—
0
0
7
98
0.71
0.30
1.0
1.1
—
—
—
0
0
10
131
0.76
0.30
1.3
1.5
15.24
16.68
umol/l
—
10
119
19
229
0.83
0.30
1.4
1.3
266.21
279.06
mosm/kgh2o
1.24
14
169
34
296
1.15
0.30
1.5
1.8
3.85
3.99
iu/l
0.03
12
99
15
185
0.81
0.29
1.0
1.1
—
31.60
—
0
5
66
603
1.10
0.28
1.9
2.1
91.65
85.60
%
1.46
66
588
49
544
0.90
0.28
1.6
1.6
36.72
32.69
u/ml
—
9
98
54
596
0.90
0.28
2.9
3.1
0.80
0.83
nmol/l
0.19
35
467
8
62
1.29
0.28
1.1
1.2
—
—
—
0
0
106
1133
0.93
0.27
1.8
2.6
3.36
2.89
g/l
3.38
88
1031
19
226
0.84
0.27
2.4
1.3
0.77
0.65
nmol/l
0.79
19
217
18
215
0.84
0.27
1.2
1.4
16.43
22.26
%
0.78
13
139
8
67
1.19
0.26
2.1
2.1
1.55
1.70
ratio
—
8
61
99
1056
0.93
0.25
1.2
1.3
108.68
67.31
au/ml
—
9
86
6
85
0.71
0.24
1.0
1.2
86.33
229.85
iu/ml
—
6
85
14
169
0.83
0.24
1.5
1.3
—
47.00
—
0
10
5
39
1.28
0.23
1.0
1.3
—
—
—
0
0
472
4609
1.03
0.22
4.7
4.2
1.02
1.02
kg/l
0.58
381
3214
5
41
1.22
0.22
1.0
1.7
124.74
37.21
pmol/l
—
5
31
5
41
1.22
0.22
1.6
1.1
—
—
—
0
0
17
199
0.85
0.21
1.2
1.1
—
—
—
0
0
37
409
0.90
0.21
1.3
1.4
—
19.99
—
0
11
5
42
1.19
0.21
1.0
1.2
1.20
140.31
mg/l
—
5
28
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
56.80
—
0
10
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
7.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
9.6
—
—
—
0
0
12
145
0.83
0.21
1.9
2.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
0.81
—
0
6
0
13
0.00
0.21
0.0
1.1
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
9
115
0.78
0.20
3.2
1.7
40.82
39.37
g/l
—
9
115
44
479
0.92
0.19
1.6
1.5
1503.47
3867.26
e6/l
0.67
32
336
14
165
0.85
0.19
1.0
1.3
1.43
1.40
g/l
0.20
14
165
11
133
0.83
0.19
1.1
1.3
57.20
220.57
ug/l
—
5
59
7
61
1.15
0.17
1.3
2.4
7.37
8.28
mmol/l
—
7
36
38
413
0.92
0.17
1.2
1.1
—
1.23
—
0
5
22
196
1.12
0.16
1.6
2.1
7.95
7.76
mmol/l
0.10
22
196
8
71
1.13
0.16
1.5
1.2
—
—
—
0
0
15
130
1.15
0.15
1.0
1.3
—
—
—
0
0
15
130
1.15
0.15
1.0
1.3
—
—
—
0
0
6
77
0.78
0.15
1.0
1.5
—
—
—
0
0
29
264
1.10
0.15
4.6
1.3
188.92
244.86
pmol/l
1.01
24
216
28
306
0.91
0.14
4.1
3.5
—
—
—
0
0
12
139
0.86
0.14
3.0
2.3
377.83
552.21
e6/l
0.76
12
119
8
97
0.82
0.13
1.3
1.2
—
—
—
0
0
39
418
0.93
0.13
1.2
1.1
—
—
—
0
0
9
106
0.85
0.13
1.0
1.1
—
—
—
0
0
13
148
0.88
0.12
1.0
1.0
—
—
—
0
0
66
692
0.95
0.12
1.4
2.6
30.97
34.81
umol/l
0.67
61
612
82
854
0.96
0.12
1.4
2.6
0.00
0.00
g/l
0.50
68
742
101
1046
0.96
0.11
1.7
2.6
9.64
10.53
g/l
1.42
80
930
40
425
0.94
0.11
1.6
1.5
55009.95
66251.51
e6/l
0.12
19
249
103
1063
0.97
0.10
1.8
2.7
1.01
1.23
g/l
0.19
79
909
11
125
0.88
0.10
1.0
1.0
—
—
—
0
0
29
271
1.07
0.09
1.2
1.5
71.19
66.42
%
0.33
21
172
5
48
1.04
0.09
1.0
1.1
—
—
—
0
0
6
54
1.11
0.09
1.0
1.1
—
—
—
0
0
6
55
1.09
0.09
1.2
1.1
1885.67
1524.44
miu/ml
—
6
55
6
56
1.07
0.08
1.0
1.1
—
—
—
0
0
71
687
1.03
0.08
1.3
1.6
—
—
—
0
0
23
215
1.07
0.07
1.4
1.3
—
—
—
0
0
31
294
1.06
0.07
1.1
1.1
1.17
23.75
iu/ml
—
6
55
9
85
1.06
0.07
1.0
1.1
—
—
—
0
0
59
609
0.97
0.06
2.2
3.5
128.17
594.77
u/ml
1.43
52
563
9
101
0.89
0.06
1.1
1.1
—
—
—
0
0
9
103
0.87
0.06
1.0
1.3
—
—
—
0
0
9
104
0.86
0.06
1.1
1.2
—
60.27
%
—
0
15
33
345
0.96
0.06
1.3
1.4
177.57
157.56
au/ml
—
7
98
12
110
1.09
0.05
1.2
1.5
8.82
1.93
u/ml
—
6
75
1741
17385
1.01
0.04
4.9
5.8
4.33
4.11
mmol/l
14.02
1556
15961
1661
16633
0.99
0.03
4.2
4.8
1.37
1.27
mmol/l
6.29
1453
14985
44
429
1.03
0.03
2.1
1.3
9.46
7.76
u/l
0.35
27
342
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
10
92
1.09
0.03
1.1
1.1
—
—
—
0
0
88
893
0.98
0.03
1.4
2.5
0.03
0.04
g/l
0.17
73
796
11
102
1.08
0.03
1.1
1.1
264.45
319.29
u/l
0.23
11
94
1723
17249
0.99
0.02
4.9
5.7
1.33
1.30
mmol/l
2.91
1528
15686
13
138
0.94
0.02
3.4
2.1
0.37
0.61
e9/l
2.33
13
128
80
789
1.01
0.02
1.5
1.8
—
—
—
0
0
27
278
0.97
0.02
1.8
3.2
—
—
—
0
0
1779
17776
1.00
0.02
5.5
6.7
2.48
2.35
mmol/l
7.20
1584
16242
34
348
0.98
0.01
4.1
5.0
9.94
11.69
pmol/l
0.61
34
348
15
143
1.05
0.01
2.1
2.2
—
—
—
0
0
235
2351
1.00
0.00
2.0
2.3
0.20
0.20
g/l
0.13
217
2175
17
168
1.01
0.00
1.4
1.2
—
—
—
0
0
32
322
0.99
0.00
1.2
1.2
347.56
295.50
u/ml
0.48
16
189
79
793
1.00
0.00
1.4
2.6
0.00
0.00
g/l
-0.00
68
742
13
133
0.98
0.00
1.1
1.3
106.54
90.29
pmol/l
0.51
13
133
5
52
0.96
-0.00
1.0
1.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
5.4
—
367.67
—
0
9
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
5
57
0.88
-0.00
1.0
1.5
293.20
230.63
%
—
5
52
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
7
74
0.95
-0.00
1.0
2.2
142.39
21.21
u/l
—
7
67
6
60
1.00
-0.00
1.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
1883.67
—
0
6
0
9
0.00
-0.00
0.0
4.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.3
—
2.27
—
0
7
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
1.46
—
0
5
5
52
0.96
-0.00
1.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: RX_L02BX – L02BX Other hormone antagonists and related agents
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).